Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force.
J Prev Alzheimers Dis
; 10(3): 418-425, 2023.
Article
em En
| MEDLINE
| ID: mdl-37357282
ABSTRACT
In randomized clinical trials (RCTs) for Alzheimer's Disease (AD), cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers are currently used for the detection and monitoring of AD pathological features. The use of less resource-intensive plasma biomarkers could decrease the burden to study volunteers and limit costs and time for study enrollment. Blood-based markers (BBMs) could thus play an important role in improving the design and the conduct of RCTs on AD. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas tau
/
Doença de Alzheimer
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Revista:
J Prev Alzheimers Dis
Ano de publicação:
2023
Tipo de documento:
Article